ANAB Quote, Financials, Valuation and Earnings

Design Therapeutics has a net margin of -141.62% compared to AnaptysBio's net margin of --. AnaptysBio's return on equity of -284.76% beat Design Therapeutics's return on equity of --.

AnaptysBio has a consensus price target of $37.82, signalling upside risk potential of 94.44%. On the other hand Design Therapeutics has an analysts' consensus of $7.33 which suggests that it could grow by 128.1%. Given that Design Therapeutics has higher upside potential than AnaptysBio, analysts believe Design Therapeutics is more attractive than AnaptysBio.

AnaptysBio has a beta of -0.204, which suggesting that the stock is 120.418% less volatile than S&P 500. In comparison Design Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Design Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. Design Therapeutics pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $27.8M, which are larger than Design Therapeutics quarterly revenues of --. AnaptysBio's net income of -$39.3M is lower than Design Therapeutics's net income of -$17.7M. Notably, AnaptysBio's price-to-earnings ratio is -- while Design Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 5.10x versus -- for Design Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -141.62% compared to AnaptysBio's net margin of -49.65%. AnaptysBio's return on equity of -284.76% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

AnaptysBio has a consensus price target of $37.82, signalling upside risk potential of 94.44%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 42.86%. Given that AnaptysBio has higher upside potential than NovaBay Pharmaceuticals, analysts believe AnaptysBio is more attractive than NovaBay Pharmaceuticals.

AnaptysBio has a beta of -0.204, which suggesting that the stock is 120.418% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $27.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. AnaptysBio's net income of -$39.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, AnaptysBio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 5.10x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -141.62% compared to AnaptysBio's net margin of --. AnaptysBio's return on equity of -284.76% beat Theriva Biologics's return on equity of --.

AnaptysBio has a consensus price target of $37.82, signalling upside risk potential of 94.44%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1134.13%. Given that Theriva Biologics has higher upside potential than AnaptysBio, analysts believe Theriva Biologics is more attractive than AnaptysBio.

AnaptysBio has a beta of -0.204, which suggesting that the stock is 120.418% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $27.8M, which are larger than Theriva Biologics quarterly revenues of --. AnaptysBio's net income of -$39.3M is lower than Theriva Biologics's net income of -$4.4M. Notably, AnaptysBio's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 5.10x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings has a net margin of -141.62% compared to AnaptysBio's net margin of -15.34%. AnaptysBio's return on equity of -284.76% beat Xeris Biopharma Holdings's return on equity of -1019.2%.

AnaptysBio has a consensus price target of $37.82, signalling upside risk potential of 94.44%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of $6.42 which suggests that it could grow by 30.95%. Given that AnaptysBio has higher upside potential than Xeris Biopharma Holdings, analysts believe AnaptysBio is more attractive than Xeris Biopharma Holdings.

AnaptysBio has a beta of -0.204, which suggesting that the stock is 120.418% less volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 0.926, suggesting its less volatile than the S&P 500 by 7.36%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $27.8M, which are smaller than Xeris Biopharma Holdings quarterly revenues of $60.1M. AnaptysBio's net income of -$39.3M is lower than Xeris Biopharma Holdings's net income of -$9.2M. Notably, AnaptysBio's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 5.10x versus 3.30x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.